Skip to content
Shagandha®
  • About Shagandha®
    • Introduction
    • Traditional Significance
    • Chemistry
    • Why Shagandha®?
      • Complies with USP monograph
      • NON-GMO Project Verified
    • Benefits
  • Research
    • Preclinical
    • Clinical
    • Publications
  • IP Rights
    • Patents
    • Trademark Licence
  • About Sabinsa
    • Newsroom
      • Press Releases
      • Shagandha® Book
      • Ads
      • FAQs
  • Contact Us

New Diabetic Research on Sabinsa’s Curcumin C3 Complex® and BioPerine® Combination Published

Two papers have been recently published reporting results of a clinical trial examining the impact of Sabinsa’s Curcumin C3 Complex® / BioPerine® combination on diabetic subjects.

Effects of Curcuminoids Plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo-Controlled Trial was published in Drug Research (Drug Res (Stuttg) 2018; 68(07): 403-409; https://www.ncbi.nlm.nih.gov/pubmed/29458218). Curcuminoids Plus Piperine Modulate Adipokines in Type 2 Diabetes Mellitus was published in Current Clinical Pharmacology 2017; 12(4):253-258; https://www.ncbi.nlm.nih.gov/pubmed/29299989).

“In a randomized, double-blind placebo-controlled trial involving a total of one hundred type-2 diabetes subjects treated with C3 Complex/BioPerine combination (500mg/5mg respectively as daily dose) or placebo for three months, the researchers found that C3 Complex/BioPerine combination improved the glycemic parameters such as glucose concentration and Hb1Ac in the blood. Decrease in both these parameters indicated a positive response to C3 Complex/BioPerine by diabetic subjects. Also, the levels of C-peptide, an indicator of the amount of insulin produced, also registered an increase in the subjects receiving the supplement over the placebo-receiving subjects. Hepatic health in the supplement-receiving subjects also improved as shown by the ALT and AST parameters. In addition, improved function of the beta cells of the pancreas, the site of insulin production, was indicated by HOMA-β values measured.Curcumin Logo
The authors also noted an increase in the values of anti-inflammatory adiponectin, an adipokine again connected with glucose maintenance and insulin sensitivity. This increase was observed along with a decreasing leptin/adiponectin ratio and lower values of leptin. The leptin/adiponectin ratio has been recognized as an indicator of atherosclerosis with lower values as a healthy indicator. The trial also indicated lower levels of pro-inflammatory cytokine TNFα in C3 Complex/BioPerine group.

“While we’ve known that our ingredients hold the keys to good health, work in this area is particularly encouraging given the prevalence and growth of Type 2 diabetes worldwide,” noted Sabinsa founder Dr. Muhammed Majeed.

These clinical results corroborate similar observations made on an animal study using C3 Complex by Columbia University researchers in 2008 [Endocrinology https://www.ncbi.nlm.nih.gov/pubmed/18403477 2008;149(7):3549-3558].

Back

About Sabinsa

Sabinsa is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

Headquarters

Sabinsa Corporation

20 Lake Drive 

East Windsor

NJ 08520, USA

 

Tel : +1 732 777 1111

Fax: +1 732 777 1443

info@sabinsa.com

Global Contact List

USAIndia
Utah, USAJapan
AustraliaPoland
BrasilKorea
CanadaSouth Africa
ChinaVietnam
Germany 

Contact us

    © 2025 Sabinsa. All Rights Reserved | Privacy Policy | Sitemap | Terms of Use | Disclaimer

    ×

    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.